ADIPOQ and diabetes mellitus: Although previous studies have shown that plasma adiponectin levels are reduced in patients with diabetes, receptors may have compensatory increases to offset certain adverse effects of reduced adiponectin and maintain protective roles, which has been observed in a few studies on kidney injury after the administration of AdipoRon [41].